Reply to letter to the editor "antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment".
作者信息
Narita Daisuke, Ebina-Shibuya Risa
机构信息
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8574, Japan.
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8574, Japan.
出版信息
Respir Investig. 2023 May;61(3):347-348. doi: 10.1016/j.resinv.2023.02.004. Epub 2023 Mar 7.
Abstract
摘要
相似文献
1
Reply to letter to the editor "antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment".对编辑来信《肺癌患者对第二剂新冠疫苗接种的抗体反应：评论》的回复
Respir Investig. 2023 May;61(3):347-348. doi: 10.1016/j.resinv.2023.02.004. Epub 2023 Mar 7.
2
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients: comment.肺癌患者对第二剂新冠疫苗接种的抗体反应：评论
Respir Investig. 2023 May;61(3):332. doi: 10.1016/j.resinv.2023.02.001. Epub 2023 Mar 1.
3
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment.肺癌患者治疗中 COVID-19 疫苗第二剂的抗体反应。
Respir Investig. 2023 Mar;61(2):247-253. doi: 10.1016/j.resinv.2022.11.005. Epub 2022 Dec 15.
4
Severe rhabdomyolysis and SARS-CoV-2 vaccination: a reply to the letter by Dr. Josef Finsterer.: Reply to Letter to the Editor regarding our report to Dr. Finsterer.严重横纹肌溶解症与新型冠状病毒疫苗接种：对约瑟夫·芬斯特勒医生来信的回复：针对芬斯特勒医生就我们的报告致编辑的信的回复。
Int J Infect Dis. 2022 Sep;122:1005. doi: 10.1016/j.ijid.2022.06.036. Epub 2022 Jun 26.
5
Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.免疫接种三剂后和突破性 COVID-19 感染前癌症患者 SARS-CoV-2 抗体水平的定量分析。
Curr Oncol. 2022 Sep 28;29(10):7059-7071. doi: 10.3390/curroncol29100554.
6
Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119-20.致编辑的信：关于接种新型冠状病毒疫苗后是什么引发了应激性心肌病？《心肺循环》。2021年；30(12):e119 - 20。
Heart Lung Circ. 2022 May;31(5):e76-e77. doi: 10.1016/j.hlc.2021.12.010. Epub 2022 Jan 19.
7
Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.肺癌患者新冠病毒疫苗接种的纵向分析：抗体反应和变异株特异性中和作用
J Clin Oncol. 2022 Nov 20;40(33):3787-3789. doi: 10.1200/JCO.22.01136. Epub 2022 Jun 27.
8
Reply to letter to editor "Cancer patients should be considered as a high-risk priority target in the COVID-19 vaccination process".致编辑信函的回复：“癌症患者应被视为新冠疫苗接种过程中的高危优先目标” 。
J Surg Oncol. 2021 Sep;124(3):455. doi: 10.1002/jso.26507. Epub 2021 Apr 20.
9
[Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].[既往感染过新冠病毒与未感染过新冠病毒的医护人员接种两剂新冠病毒灭活疫苗后的抗体反应：一项前瞻性观察研究]
Mikrobiyol Bul. 2022 Jan;56(1):36-48. doi: 10.5578/mb.20229904.
10
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls.血液透析患者在接种 COVID-19 mRNA 疫苗后的抗体反应明显低于健康对照者。
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716. doi: 10.1093/ndt/gfab179.
本文引用的文献
1
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment.肺癌患者治疗中 COVID-19 疫苗第二剂的抗体反应。
Respir Investig. 2023 Mar;61(2):247-253. doi: 10.1016/j.resinv.2022.11.005. Epub 2022 Dec 15.
2
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.评估癌症患者的 COVID-19 疫苗反应：一项中期分析。
Eur J Cancer. 2021 Dec;159:259-274. doi: 10.1016/j.ejca.2021.10.013. Epub 2021 Oct 25.
3
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.癌症患者 COVID-19 疫苗接种后对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的免疫原性和风险：系统评价和荟萃分析。
Eur J Cancer. 2022 Jan;160:243-260. doi: 10.1016/j.ejca.2021.10.014. Epub 2021 Oct 26.
4
Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.接种 COVID-19 疫苗后癌症患者的血清转化率：系统评价。
Ann Oncol. 2022 Feb;33(2):158-168. doi: 10.1016/j.annonc.2021.10.014. Epub 2021 Oct 28.
5
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.血液肿瘤患者和接受 SARS-CoV-2 疫苗接种的医护人员的体液免疫反应。
JAMA Oncol. 2022 Jan 1;8(1):106-113. doi: 10.1001/jamaoncol.2021.5437.
6
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.BNT162b2新冠疫苗用于实体癌患者的免疫原性和安全性：来自单一机构的大型队列前瞻性研究
Clin Cancer Res. 2021 Dec 15;27(24):6815-6823. doi: 10.1158/1078-0432.CCR-21-2439. Epub 2021 Sep 28.
7
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
8
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
9
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.美国癌症和 COVID-19 感染患者的风险、种族差异和结局分析。
JAMA Oncol. 2021 Feb 1;7(2):220-227. doi: 10.1001/jamaoncol.2020.6178.
Zotero 插件